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Scleroderma lung involvement, autoantibodies and outcome prediction: the confounding effect of 
time 
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Systemic sclerosis (SSc) remains a poorly understood disease and so far none of the routinely used 
immunosuppressive treatments has been definitively shown to benefit long-term disease outcome. 
Scleroderma-related cardio-pulmonary involvement has been the leading cause of death in more recent 
decades and pulmonary fibrosis (PF) and pulmonary hypertension (PH) account for a substantial 
proportion of the SSc-related deaths, as demonstrated by several large meta-analyses (1-3).  
Early detection and monitoring of PF and PH may benefit outcome by permitting earlier intervention in 
severe or progressive cases. Multiple attempts have been made to develop prediction models both for 
development and for outcome in already present SSc-related lung disease. Consistently, autoantibody 
specificities are among the strongest, but not the only, predictors of organ disease in scleroderma 
patients and autoantibody characterisation is a mandatory part of the work-up of new SSc cases.  
It is well established that while positivity for anti-centromere antibodies (ACA) is associated with the 
limited cutaneous subset of the disease and a low risk of pulmonary or renal involvement, presence of 
anti-topoisomerase I antibodies (ATA) convey a substantially increased risk of PF development and anti-
RNA polymerase antibodies (ARA) are strongly associated with the diffuse cutaneous subset (dcSSc) and 
development of scleroderma renal crisis (SRC) (4). Most cohort studies describe no particular association 
between ARA positivity and PH or PF development. Although this was true in an unadjusted analysis, 
when correcting for other variables, ARA positivity was shown to associate with an increase in the 
hazard of PH development in a large single-centre cohort analysis (5). In addition, compared to ACA 
positive patients, those carrying ARA have been shown to develop PF more frequently (6, 7).  
Several studies have assessed and compared the value of pulmonary function tests (PFTs) and high-
resolution computed tomography (HRCT) for the screening and monitoring of PF and even though HRCT 
appears to be a more accurate tool (8, 9), the associated cost and radiation burden means that serial 
PFTs remain the preferred method for long-term PF monitoring.  An algorithm combining results from 
HRCT and PFTs was developed by Goh et al. and seems to have a very good prognostic value, allowing 
for an easy and quick staging of lung disease and assessment of the need for immunosuppressive 
treatment (10). 
In this issue, the article by Hoffman-Vold et al. focuses on SSc-related cardio-pulmonary complications in 
a group of patients with well-characterised autoantibody profiles and looks for specific patterns 
associated with ARA positivity. This is a prospective observational study, presenting a well-characterised 
cohort of SSc patients with very robust associated clinical data. Lung complications have been 
ascertained using gold-standard tests with serial PFTs and HRCT scanning used to define PF, while all PH 
cases were confirmed using right heart catheterisation.   
Similar to previous cohort studies, the authors find no association between ARA positivity and the 
overall risk of development of PF with nearly half of the ARA positive patients (49%) having no evidence 
of PF development over the duration of the study. Nevertheless, 18% of the ARA positive patients did 
develop extensive PF, affecting more than 20% of the lung on HRCT, emphasizing the importance of PF 
screening in all SSc patients, irrespective of their presumed risk of this complication.  
Moreover, a particularly interesting finding is that among ARA positive patients who did develop PF, 
extensive fibrosis tended to develop later on in the disease course. This was unlike the ATA positive 
cohort, where the great majority of subjects who were to develop extensive PF already had it at 
baseline. This is in keeping with the findings of a recent observational cohort study of 294 patients from 
Thailand, where disease duration at first detection of PF was much shorter in ATA positive compared to 
ATA negative patients (11). It also reflects the fact that association between PF development and ATA 
positivity has a significant interaction with disease duration with hazard of PF doubling after 5 years of 
disease (5).  
There could be multiple explanations for the apparently different course of progression in PF in subjects 
with ATA and ARA, and different pathophysiological mechanisms for the fibrotic changes development 
are likely. For ATA positive patients these may be autoimmune inflammation-driven while in patients 
with ARA, PF progression could be perpetuated by gastro-oesophageal reflux with associated micro-
aspiration or recurrent infections, leading to alveolar epithelial injury occurring later in the disease 
course, which could account for the later development of extensive disease in those subjects (12, 13). 
One major confounder in the study by Hoffman-Vold et al. is the significant difference in disease 
duration at study baseline between the ARA positive and ATA positive patients, where those carrying 
ATA had on average 3 years longer disease duration than subjects carrying ARA. Given that clinically 
significant PF generally develops early in the disease and multiple studies have shown that this happens 
to the majority of patients within the first 5 years from onset (5, 14, 15), it is not surprising that most 
ATA positive patients who were going to develop significant PF had already reached this endpoint, given 
that mean disease duration at baseline in this group was 6.2 years, compared to 3.3 years for ARA 
positive patients. This highlights the importance of accounting for disease duration in any research into 
outcome prediction in SSc patients. 
SSc has a very specific natural pattern of progression. As a result, the timing of peak skin disease and 
major organ complications, if they are to develop, could be anticipated. Thus, skin involvement in 
patients with dcSSc, as measured by the modified Rodnan skin score (mRss), tends to worsen 
comparatively rapidly in the initial stages of the disease. The majority of patients with the diffuse subset 
of SSc reach their peak mRss within the first three years from first non-Raynaud's onset and skin tends 
to improve thereafter in approximately 80% of the subjects (16, 17). Deterioration in skin disease or new 
development of worsening skin thickening in patients with disease duration longer than 5 years is 
extremely rare and often a sign of an underlying more sinister pathology.  
Similar to the natural evolution of skin disease, major organ complications, with the obvious exception 
of PH, normally develop in the early stages of SSc and could be even a presenting feature (4, 17). For 
example, incidence of SRC is highest in the first 3 years of disease, significantly lessening in later years 
with only anecdotal cases of SRC developing 10 years or longer after SSc onset (18). Clinically significant 
PF (defined as FVC or DLCO of less than 55% or a drop in FVC or DLCO of more than 15% from first 
assessment) also tends to develop earlier on, with over 2/3 of the subjects who are to develop this 
endpoint, reaching it in the first 5 years from disease onset (5). On the other hand, PH does develop 
later in the disease course, with apparently constant incidence rate over time, suggesting that longer 
follow-up will be associated with a greater probability of PH development in a given subject.  
As a result, any study investigating predictors of organ complications in systemic sclerosis should take 
into account the timing of those complications and the disease duration in the study subjects. Time to 
event analysis rather than simple associations between explanatory variables and present/absent 
outcomes should be considered and interaction between any of the predictor variables and time should 
be tested as appropriate. 
In this context, the study by Hoffman-Vold et al. is a good illustration of many of the challenges 
associated with studying a rare disease with variable presentation, and a specific course of progression 
that can affect the studied associations, if not adjusted for in the analysis. In this case, although the 
numbers were reasonable for a scleroderma study, they were still insufficient to allow for a 
comprehensive multivariable analysis. One inevitable conclusion from this paper is that there is real 
need for even more detailed and larger studies, assessing the effect of autoantibody specificities on the 
outcome of lung complications in scleroderma patients. At a practical level, these findings reassert the 
clinical importance of ongoing monitoring of SSc patients for potential lung complication development. 
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